Eyal Rubin serves as Executive at BRAINSTORM CELL THERAPEUTICS INC., where they oversee executive responsibilities. Since joining the company, Eyal Rubin has executed 6 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Sep 23, 2024 involved receiving (via award) 99,010 shares valued at $0.
Eyal Rubin currently holds 669,010 shares of BRAINSTORM CELL THERAPEUTICS INC. (BCLI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Eyal Rubin has been a net neutral trader of BCLI stock. They have purchased $0 and sold $0 worth of shares.
Eyal Rubin's most recent insider trade was on Sep 23, 2024, when they sold 99,010 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Feb 25, 2022 | PLX | $0 | Award | 121,951 | $N/A | Discretionary |
| Aug 11, 2020 | PLX | $0 | Award | 246,146 | $N/A | Discretionary |
| Aug 11, 2020 | PLX | $0 | Award | 246,146 | $N/A | Discretionary |
| Nov 20, 2017 | BCLI | $0 | Award | 25,000 | $N/A | Discretionary |